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Porokeratotic Eccrine Nevus May Be Caused by
Somatic Connexin26 Mutations
Jennifer A. Easton1,2,7, Steven Donnelly3,7, Miriam A.F. Kamps1,2, Peter M. Steijlen1,2,
Patricia E. Martin3, Gianluca Tadini4, Rene´ Janssens5, Rudolf Happle6, Michel van Geel1,2 and
Maurice A.M. van Steensel1,2
Porokeratotic eccrine ostial and dermal duct nevus, or porokeratotic eccrine nevus (PEN), is a hyperkeratotic
epidermal nevus. Several cases of widespread involvement have been reported, including one in association
with the keratitis–ichthyosis–deafness (KID) syndrome (OMIM #148210), a rare disorder caused by mutations in
the GJB2 gene coding for the gap junction protein connexin26 (Cx26). The molecular cause is, as yet, unknown.
We have noted that PEN histopathology is shared by KID. The clinical appearance of PEN can resemble that of
KID syndrome. Furthermore, a recent report of cutaneous mosaicism for a GJB2 mutation associated with
KID describes linear hyperkeratotic skin lesions that might be consistent with PEN. From this, we hypothesized
that PEN might be caused by Cx26 mutations associated with KID or similar gap junction disorders. Thus, we
analyzed the GJB2 gene in skin samples from two patients referred with generalized PEN. In both, we found
GJB2 mutations in the PEN lesions but not in unaffected skin or peripheral blood. One mutation was already
known to cause the KID syndrome, and the other had not been previously associated with skin symptoms. We
provide extensive functional data to support its pathogenicity. We conclude that PEN may be caused by mosaic
GJB2 mutations.
Journal of Investigative Dermatology (2012) 132, 2184–2191; doi:10.1038/jid.2012.143; published online 17 May 2012
INTRODUCTION
The term ‘‘porokeratotic eccrine ostial and dermal duct nevus’’
was first used by Abell and Read (1980) to describe a hard,
verrucous epidermal nevus. Histopathological features typically
include ortho- or parakeratotic plugs protruding from dilated
(eccrine) ducts and follicular openings. Depending on sectioning,
these plugs can appear as so-called cornoid lamellae. In addition,
hyper(para)keratosis and wavy psoriasiform epidermal acanthosis
can also be present (Aloi and Pippione, 1986). Comedo-like or
spiky lesions can be prominent in porokeratotic eccrine nevus
(PEN) when located on the palms or soles (Sassmannshausen
et al., 2000). Several cases of bilaterally systematized lesions of
PEN affecting large areas of the body have been reported (Cobb
et al., 1990; Kroumpouzos et al., 1999; Cambiaghi et al., 2007;
Goddard et al., 2009). Happle and Rogers (2002) recently
proposed the more compact designation ‘‘PEN’’.
The molecular cause is, as yet, still unknown. However,
we have noted that the characteristic cutaneous histopathol-
ogy is shared by the keratitis–ichthyosis–deafness (KID)
syndrome (OMIM #148210). This rare disorder is caused by
mutations in the GJB2 gene coding for the gap junction
protein connexin26 (Cx26; van Steensel et al., 2002). KID
syndrome histopathology typically shows dilated follicular
and eccrine duct openings with a preserved granular layer
and ortho-/parakeratotic plugs that can appear as cornoid
lamellae. The epidermis shows wavy psoriasiform acanthosis.
Clinically, the ichthyosis in KID is characterized by general-
ized figurate erythema and cobblestone-like or spiky hyper-
keratosis (de Zwart-Storm et al., 2009). Thus, KID syndrome
can appear as a generalized form of PEN. Two of the authors
(PS and RH) have personally seen a newborn with lethal
KID syndrome born to a women diagnosed with PEN.
They initially diagnosed the child with ‘‘generalized PEN’’,
which was later revised (Steijlen P, personal communication).
Titeux et al. (2009) recently described mosaicism for a
Cx26 mutation causing the previously reported substitution
p.Asp50Asn (D50N) in the mother of a child with KID
syndrome. The mother had a short stature and bilateral linear
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hyperkeratotic skin lesions on the trunk. Unfortunately, the
photographs provided in that report were of insufficient
quality to confidently make a diagnosis, but the abnormalities
might be consistent with PEN. Finally, cases of nonsegmental
KID syndrome were recently reported to be ‘‘associated with
PEN’’, on the grounds of purely histopathological findings
(Criscione et al., 2010; Lazic et al., 2011). Considering the
above, we hypothesized that PEN might be caused by Cx26
mutations associated with KID syndrome or similar hyperker-
atotic gap junction disorders (de Zwart-Storm et al., 2009).
Thus, we analyzed the GJB2 gene in skin and blood samples
from two patients who were referred with widespread PEN,
confirmed by histopathological examination (Figure 1). Both
patients were otherwise healthy and had no other symptoms
besides skin lesions.
RESULTS
Case reports
Clinical examination of patient 1, from Italy, showed wide-
spread spiky hyperkeratotic papules and plaques with linear
distribution on the extremities, and mostly diffuse palmo-
plantar involvement (Figure 1a–c). The nails of both hands
and the left foot were dystrophic. The abnormalities had been
present since birth and were not progressive. There were no
mucosal abnormalities. Hair and teeth were normal. There
was no hearing loss, and family history was negative. Several
biopsies were taken from affected sites and sent for
histopathological examination. All showed abnormalities
that were deemed consistent with PEN (Figure 1i–j). Patient
2, from the Netherlands, had less widespread involvement,
presenting with linear spiky hyperkeratotic plaques on both
feet and geographic brown-red plaques with a sharply
demarcated border in a linear distribution on the trunk and
proximal extremities (Figure 1d–f). The skin lesions had been
present all his life and were not progressive. Hearing loss
was not present. Family history was negative. A biopsy taken
from the trunk showed similar abnormalities to those in
patient 1 (Figure 1k and l). Both patients were diagnosed as
having PEN.
Mutation analysis indicates somatic mosaicism
In both patients, we detected mutations within the GJB2
gene in samples from all biopsied disease sites. Specifically,
three sites were sampled in patient 1 (foot sole, knee, and
trunk) and two sites in patient 2 (axilla and trunk). We
could only amplify wild-type (WT) GJB2 from unaffected skin
(one sample per patient, Figure 2a and b) and peripheral
blood leukocytes (not shown). Patient 1 had a transition
c.40A4T (Figure 2a) causing the known KID-associated
amino acid change p.Asn14Tyr (N14Y, Arita et al., 2006);
patient 2 had a transversion c.279G4A (Figure 2b) causing
the substitution p.Met93Ile (M93I). We also sequenced
the GJB6 gene, as there are reports suggesting that mutations
in GJB6 can cause disorders resembling those associated
with GJB2 (Jan et al., 2004). No GJB6 mutations were
found in either patients. Although N14Y is known to be
pathogenic (Arita et al., 2006; de Zwart-Storm et al., 2011),
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Figure 1. Clinical and histopathological phenotypes. Phenotype of patient 1,
showing circumscript spiky hyperkeratosis with linear distribution in the axilla
(a) and knee flexure (b). The feet are more diffusely affected (c). Phenotype of
patient 2, showing linear hyperkeratotic plaques with spiky surface on the foot
(f) and linear, sharply demarcated geographic plaques elsewhere with a
smooth surface (d, e). Histopathology is shown in panels g–l. Normal skin
section shown in g ( 5) and h (10). Biopsy taken from the foot of patient 1
(i,  10; j,  100) shows a dilated eccrine duct with parakeratotic lamellae
(i, j); sample from the trunk taken from the Dutch patient (k,  5; l10)
shows wavy epidermis with psoriasisform acanthosis and basket-weave
hyperkeratosis. Marked square area denotes magnified area for h, j, k.
Bar¼300 mm (except j¼ 30 mm).
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M93I has not previously been reported in conjunction with
cutaneous abnormalities.
We performed additional investigations to determine
whether M93I is a pathogenic change.
Affected skin shows hyperproliferation and altered Cx26
expression patterns
Skin biopsies from the two patients were stained for Cx26 plus
a number of cell proliferation/differentiation markers and
compared with normal skin tissue (Figure 3). In both normal
tissue (Figure 3a) and N14Y patient tissue (Figure 3b), Cx26
was observed in the cornified layer as well as within the
spinous and granular layers. The pattern in normal skin
is consistent with previous reports (Richard et al., 2002).
Within the M93I patient tissue (Figure 3c), however, Cx26
expression was only observed within the spinous and granular
layers and not in the cornified layer. In control skin, Cx26
staining has a dense punctate distribution, at points of cell-to-
cell contact. Biopsies from the patient harboring the N14Y
mutation, in contrast, displayed a more dispersed punctate
pattern of staining. Interestingly, M93I expression is inter-
mediate, the staining being accentuated in certain membrane
localizations. Expression of cytokeratin10 (CK10), an early
differentiation marker, was greatly increased in both N14Y
and M93I patient tissues in comparison with normal tissue, as
was loricrin expression (a marker of terminal differentiation).
To determine whether the N14Y and M93I mutations resulted
in an increase in cellular proliferation, tissues were stained
with Ki67. In addition, tissues were co-stained with the basal
cell marker CK14. Ki67þ cells were present within the basal
layer of normal and patient tissue; however, the percentage of
Ki67þ /CK14þ cells was increased in both patient
tissue samples. In normal tissue, 19.1% (±1.87% SEM)
cells had double-positive staining, whereas patient 1 had
25.7% (±6.3% SEM) and patient 2 had 26.5% (±5.8%
SEM). These differences were not found to be statistically
significant.
M93I-GFP traffics to the cell membrane and forms large gap
junction plaques
HeLa Ohio cells (which do not express endogenous connex-
ins) were transfected with Cx26WT-mCherry alone (Figure 4a),
M93I-GFP alone (Figure 4b), or both Cx26WT-mCherry
and M93I-GFP (Figure 4c). As with Cx26WT-mCherry expres-
sion, M93I-GFP was observed both at the plasma membrane
and within the cytoplasm as intracellular stores. Co-transfec-
tion of Cx26WT-mCherry with M93I-GFP showed clear co-
localization. From this, we concluded that the M93I mutation
does not disrupt interaction with Cx26WT. In addition, M93I-
GFP formed large gap junction plaques at points of cell-to-cell
contact, highly separated from intracellular regions as denoted
by co-staining with the endoplasmic reticulum–Golgi inter-
mediate compartment (ERGIC) marker p58 (Figure 5b). We
can conclude from this that the M93I mutation has no adverse
effect on trafficking, unlike the D66H mutation, which
remains trapped in intracellular areas (Figure 5c).
Junctional functionality measured by dye transfer is not affected
by the M93I mutation
As aberrant connexin signaling is associated with a range of
Cx26-related disorders, we assessed the ability of M93I-GFP
to form functional gap junctions and hemichannels. A variety
of assays are widely used to determine gap junction coupling
efficiency. These include microinjection analysis, in which
coupling efficiency is determined by the extent of transfer of
small fluorescent dyes of differing charge and mass (e.g.,
Easton et al., 2009), and parachute assays, which determine
the transfer of the fluorescent probe calcein AM (molecular
weight¼623Da, charge 4). The latter have been widely
used by ourselves and others in the field (Ziambaras et al.,
1998; Du¨rig et al., 2000; Rudkin et al., 2002). In the present
work, we performed parachute assays between HeLa Ohio
cells transfected with the different complementary DNA
constructs and HeLa26 cells that stably express Cx26 (Figure
6a). In this case, it is evident that both untransfected HeLa
Ohio cells and those transfected to express D66H-GFP were
unable to form functional gap junction channels, as can be
seen by the restricted spread of calcein to adjoining cells
(Figure 6a). By contrast, cells transfected with either
Cx26WT-GFP or M93I-GFP were able to transfer dye to
HeLa26 cells, illustrating formation of functional gap junction
channels by the M93I mutations. There was no statistically
significant difference between the two groupings (Figure 6b).
We can be certain that the observed dye transfer is due
to channel formation between the transfected HeLa Ohio
cells and the HeLa26 cells, because both non-transfected
HeLa Ohio cells and those transfected with D66H-GFP
c.40A>T
c.279G>A
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Figure 2. Sequence traces showing the presence of GJB2 mutations (arrows)
in lesional (bottom panels) but not in unaffected skin (top panels). Patient 1
has a transition c.40A4T mutation (N14Y) (a), whereas patient 2 presents
with a transversion c.279G4A mutation (M93I) (b). Reduced peak height at
mutation point is indicative of mosaicism.
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(associated with Vohwinkel’s syndrome and known to be
nonfunctional) showed no transfer.
In addition to the ability to form functional gap junctions,
we investigated the effect of M93I-GFP expression on
hemichannel signaling. Exposing connexins to zero calcium
conditions is a robust method to induce hemichannel
openings that can be monitored by ATP release and
subsequently blocked by a range of connexin hemichannel
blockers (Leybaert et al., 2003). In HeLa Ohio cells
transfected to express a control vector (GFP) or the Cx26
mutation D66H-GFP, no ATP release was detected following
the calcium switch. By contrast, in cells transfected with
Cx26WT-GFP or M93I-GFP, a significant release in ATP was
observed, which was blocked upon co-incubation with the
hemichannel blocker carbenoxolone (Figure 6c). Measured
ATP release was lower in M93I-GFP-expressing cells than
was observed for those expressing Cx26WT-GFP, although
this was not statistically significant.
DISCUSSION
On the basis of our experimental findings, we suggest that
PEN can be associated with somatic mutations in GJB2
coding for the gap junction protein Cx26. We found two
distinct amino acid substitutions in two unrelated patients.
One mutation, N14Y, is a known pathogenic change that has
been reported in conjunction with disorders resembling the
KID syndrome (Arita et al., 2006; de Zwart-Storm et al.,
2011). The second mutation, M93I, has been previously
reported in trans with the deafness-associated truncating
mutation c.del35G (Wu et al., 2002). It is not clear from that
report whether or not that particular patient had skin
symptoms. If not, the change may not have been pathogenic
to the skin, or may have caused only very mild symptoms that
were missed. Another, more intriguing, explanation might be
that mutations in Cx26 associated with skin disease only
cause symptoms in trans with a WT allele. The latter
hypothesis would be consistent with the observation that
Cx26
Cx26
Cx26
CK10
CK10
CK10
Loricrin
Loricrin
Loricrin
CK14/Ki67
CK14/Ki67
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Figure 3. Immunohistological comparison of normal and patient tissue. Tissue sections from normal (a), patient 1 (b), and patient 2 (c) skin were stained
with connexin26 (Cx26), cytokeratin10 (CK10), and loricrin (all green). In addition, tissue was co-stained with Ki67 (red) and CK14 (green) to identify
proliferating cells in the basal layer. Nuclei stained with 40-6-diamidino-2-phenylindole. Patient skin shows a clear increase in CK10 and loricrin staining
plus an increase in Ki67-positive cells in the basal layer. Interestingly, no Cx26 staining was observed in the stratum corneum of patient 2. For both patients,
overall Cx26 staining seems to be less intense than that of wild type (a). In addition, patient 2 (M93I) shows plaque formation, in contrast to patient 1 (N14Y).
For orientation purposes, the basal layer is indicated by a dotted white line. Bar¼ 30mm.
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mutations in Cx26 causing cutaneous symptoms are
dominant. Previous observations of trans-dominant effects
from mutant Cx26 on Cx43 also support this idea (Rouan
et al., 2001). It will be interesting to pursue this notion in
future research. Our finding of the mutation in affected skin
only and not in unaffected areas or peripheral blood further
Cx26WT
Cx26WT
M93I
M93I
c
b
a
DAPI
DAPI
Merge
Merge
Merge
Figure 4. M93I-GFP traffics normally to the plasma membrane and co-localizes with Cx26WT-mCherry. HeLa Ohio cells were transfected with Cx26WT-
mCherry (a, red), M93I-GFP (b, green), or both Cx26WT-mCherry and M93I-GFP (c), and protein localization was analyzed after 24 hours. In both single and
double transfected cells, Cx26WT-mCherry and M93I-GFP expression was observed both within the cytoplasm (white arrow heads) and at the plasma
membrane (white arrows), indicating cellular stores and connexin (Cx) trafficking to the membrane. Cx26WT-mCherry and M93I-GFP co-localized
throughout the cell (yellow) and formed visible gap junction plaques at points of cell-to-cell contact. Nuclei are stained with 40-6-diamidino-2-phenylindole
(DAPI; blue). Bar¼20 mm.
a b c
Figure 5. HeLa Ohio cells were transfected with Cx26WT-GFP, M93I-GFP, or D66H-GFP (green) and expression analyzed 24hours post transfection. Cells were
stained with the endoplasmic reticulum–Golgi intermediate compartment marker p58 (red). Co-localization of Cx26 protein with p58 was observed with
all Cx26 transfectants (white arrow heads), indicative of intracellular stores and Cx trafficking pathways. Large gap junction plaques are clearly seen at points of
cell-to-cell contact for both Cx26WT-GFP and M93I-GFP (a and b, respectively, white arrows). D66H-GFP was used as a control, as this is a Cx26 mutation
known not to traffic; no gap junctions were observed in D66H-GFP-expressing cells (c). Nuclei stained with 40-6-diamidino-2-phenylindole (blue). Bar¼ 20 mm.
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argues in favor of its pathogenicity. To provide more pertinent
proof, we conducted additional studies. Our experiments
illustrate that M93I maintains many of the functional
parameters of Cx26WT as measured by our assays. Unlike
mutations associated with conditions such as Vohwinkel’s
syndrome, where the protein is restricted to intracellular
locations and does not form hemichannels or gap junctions in
homotypic conformations (Bakirtzis et al., 2003; Marziano
et al., 2003), M93I targets to the cell membrane and forms
both hemichannels and gap junctions. Our parachute assays
demonstrate that M93I is able to form functional channels, in
contrast to D66H. On the basis of calcein dye transfer, gap
junctions composed of M93I have functional properties
similar to Cx26WT, although it is possible that permeability
to other dyes might be altered. We have previously
demonstrated that alterations in the size of the dye do not
correlate with disease severity (de Zwart-Storm et al., 2008)
and therefore decided not to pursue this particular property of
gap junctions. The zero calcium switch experiment clearly
illustrates that M93I retains the ability to form hemichannels.
Aberrant or enhanced hemichannel activity has been
implicated in the pathogenesis of KID syndrome (Lee et al.,
2009). Compared with Cx26WT, we find that, for M93I, ATP
release upon zero calcium switching is marginally reduced.
From this, we tentatively conclude that hemichannel
behavior might be affected by mutation M93I, and other
assays including electrophysiology comparisons may eluci-
date these changes further in the future. Importantly,
immunofluorescence analysis of CK10 and Ki67 expression
in affected skin from both patients clearly indicates increased
keratinocyte proliferation, which is consistent with earlier
reports describing epidermal hyperproliferation due to Cx26
mutations. The increased loricrin staining supports this
interpretation. We also see altered spatial localization of
Cx26 in patient samples (the antibody does not distinguish
mutant from WT), and this may contribute to the pathogen-
esis of the disorder. It is noteworthy that the expression
of both mutant forms is reduced, and M93I is no longer
found in the stratum corneum as opposed to N14Y and WT.
These differences between patients and controls likely
cannot be ascribed to the biopsy site, as there are no
significant regional variations in cutaneous Cx26 expression
(Richard et al., 2002).
At present, we do not know what consequences the
altered epidermal Cx26 expression patterns have for skin
function. However, our observations would suggest that loss
of function resulting from reduced Cx26 levels might
contribute to epidermal hyperproliferation. We note that
M93I seems to still form gap junction plaques (Figure 3c), in
contrast to N14Y (Figure 3b), which shows a more diffuse
distribution consistent with lack of gap junction formation.
From the above data, we conclude that M93I is
likely a pathogenic change, but expression of M93I does
not impact Cx26 function as severely as N14Y expression, as
measured by our assays. This might be reflected in the
clinical presentation. Whereas the Italian patient had the
hyperkeratotic skin changes typically observed in KID
syndrome, the Dutch patient had altogether less pronounced
lesions. It is conceivable that the less pronounced phenotype
correlates with the milder impact of M93I on Cx26 function.
The clinical differences are reflected in the histopathology,
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Figure 6. M93I-GFP forms functional gap junctions with Cx26WT. HeLa
Ohio cells transfected with relevant complementary DNA constructs were
layered onto a monolayer of HeLa26 cells labeled with DiLC (red) (a). Dye
transfer was observed between HeLa Ohio cells transfected with either
Cx26WT-GFP or M93I-GFP and HeLa26 cells, but not between cells
transfected with GFP alone or D66H-GFP and HeLa26 cells. Bar¼20 mm. The
number of cells a ‘‘donor’’ cell transferred dye to was calculated (b). In
addition, hemichannel activity via ATP release was examined in HeLa Ohio
cells transfected with GFP alone, Cx26WT-GFP, M93I-GFP, or D66H-GFP (c).
Results were calculated as nM ATP released per mg of protein and are
expressed as a fold increase in ATP release. N¼ 3, **Po0.05; *Po0.01.
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which shows much milder abnormalities in the Dutch
patient.
From our findings, we conclude that PEN could be caused
by different somatic Cx26 mutations. There may be a
genotype–phenotype correlation, and it will be of consider-
able interest to determine the causative mutation in further
cases of PEN. Our findings also illustrate that our assays for
Cx26 function do not always predict whether or not a
mutation is pathogenic, raising questions as to the mechan-
ism by which mutations in Cx26 cause disease and under-
scoring the need for analysis of patient material.
MATERIALS AND METHODS
Sequencing and site-directed mutagenesis
GJB2 WT gene was cloned into the vectors peGFP-N1 (BD
Biosciences, Breda, The Netherlands) and pmCherry-N1 (Clontech,
via Westburg BV, Leusden, The Netherlands) as previously reported
(de Zwart-Storm et al., 2007), yielding the constructs GJB2-GFP
(coding for Cx26WT-GFP) and GJB2-mCherry (coding for Cx26WT-
mCherry). Primer sequences used for GJB2 cloning were 50-gaattc
GCCCAGAGTAGAAGATGGATTGG-30 (forward, EcoRI adapter in-
dicated in lowercase) and 50-ggatccGCAACTGGCTTTTTTGACTTC-30
(reverse, BamHI adapter in lowercase). We then introduced the
c.279G4A (M93I) mutation into the GJB2-GFP construct with site-
directed mutagenesis using KOD proof-reading enzyme (Novagen,
Merck BV, Schiphol-Rijk, The Netherlands), which yielded the
construct GJB2(c.279G4A)-GFP (coding for Cx26(M93I)-GFP, termed
M93I-GFP). Primer sequences were 50-GCCAGCGCTCCTAGTGGC-
CATACACGTGGCC-30 (forward) and 50-GTCTCCGGTAGGCCACG
TGTATGGCCACTAG-30. Mismatched nucleotides are in boldface and
italics. Clones were selected and checked as to whether they
contained the mutation before transfection into cells. Patient DNA
was isolated from 3-mm punch biopsies from which dermis
was removed using the Qiagen Maxi-prep kit (Qiagen, Venlo,
The Netherlands) according to the manufacturer’s instructions.
Sequencing was performed by LGC genomics. These studies are
covered under an umbrella agreement that has been approved
by the Maastricht University ethics committee, number: 06-1-035.
As part of the agreement, we have permission to use patient
samples for study purposes and express written consent is not
necessary. Mutation analysis is performed in regular diagnostics
services and is as such not subject to research agreements.
The study conformed to the Declaration of Helsinki Principles.
Cells and cell culture
All cell lines were cultured at 37 1C in 5% CO2. HeLa Ohio cells
were maintained in DMEM (Lonza, Breda, The Netherlands)
supplemented with 10% fetal calf serum and L-glutamine (2mM).
HeLa26 cells (HeLa Ohio cells stably transfected to express Cx26)
were maintained in DMEM supplemented with 10% fetal calf serum,
L-glutamine (2mM), and puromycin (0.5 mgml1).
For immunofluorescence studies, cells (B2 105) were cultured
on 16-mm2 glass coverslips (Fisher Scientific, Loughborough, UK) in
12-well, sterile tissue culture plates (Greiner Bio-One, Stonehouse,
UK). For parachute assay, setup cells (B2 105) were cultured in
12-well, clear, sterile tissue culture plates. For ATP assay prepara-
tion, cells (B2 103) were cultured in 96-well, clear, sterile tissue
culture plates (Greiner Bio-One).
Transfections
Cells were transfected for 24 hours with appropriate complementary
DNA at 1mg (12-well plate) or 0.2 mg. (96-well plate) using
Lipofectamine 2000 according to the manufacturer’s instructions
(Invitrogen, Paisley, UK).
Immunohistochemistry
Skin sections were cut (10 mm) from paraffin-embedded biopsies of
normal and patient tissue. Following antigen retrieval using citrate
buffer, sections were stained with Cx26 (1:50, Invitrogen), CK10 and
CK14 (neat, MuBio, Maastricht, The Netherlands), loricrin (1:400,
Abcam, Cambridge, UK), and Ki67 (1:100, Leica, Valkenswaard,
The Netherlands). Secondary antibodies used for single stains were
either Rabbit anti-Mouse-FITC or Swine anti-Rabbit-FITC (1:100,
Dako, Heverlee, Belgium) antibody. For double stains, Goat
anti-Mouse-FITC and Goat anti-Rabbit-Texas Red (1:80, Southern
Biotech, ITK Diagnostics, Uithoorn, The Netherlands) secondary
antibodies were used. Nuclei were stained with 40-6-diamidino-
2-phenylindole (0.5 mgml1). Sections were examined using a Leica
confocal microscope. Images were analyzed using the ImageJ
software (http://rsbweb.nih.gov/ij).
Immunofluorescence
The ERGIC was stained using anti-ERGIC-53/p58 (1:100, Sigma-
Aldrich, Dorset, UK). Goat anti-Rabbit conjugated to Alexa 488
(Invitrogen) was used as the secondary antibody. The nuclei of
the cells were stained blue using 40-6-diamidino-2-phenylindole
(2.5 mgml1; Sigma-Aldrich). Slides were viewed on a Zeiss LSM 510
Meta confocal microscope (Carl Zeiss, Welwyn Garden City, UK).
Images were analyzed using ImageJ.
Parachute assays
HeLa26 cells were stained with cell tracker cm-DIL (1 mgml1;
Invitrogen) for 5minutes at 37 1C and then for 15minutes at 4 1C.
After staining, cells were washed thoroughly with phosphate-
buffered saline. HeLa Ohio cells transfected with Cx26 constructs
were loaded with calcein AM (2.5 mM; Invitrogen) by incubating
at 37 1C in 5% CO2 for 30minutes. After thorough washing with
phosphate-buffered saline, cells were trypsinized and seeded
onto confluent monolayers of HeLa26 cells. Cells were incubated
for B5hours, and dye transfer patterns were analyzed using a Zeiss
LSM510 scanning confocal microscope. ImageJ was used to quantify
the data (method adapted from Ziambaras et al., 1998).
ATP assays
Cells were washed in phosphate-buffered saline and incubated in
DMEM for 1 hour at 37 1C in 5% CO2; to block hemichannel activity,
cells were incubated for 1 hour in DMEM with 100 mM carbenox-
elone. To determine hemichannel activity, cells were then chal-
lenged, for 2.5minutes, with Ca2þ -free phosphate-buffered saline
(calcium switch); DMEM was used for control cells. The media were
then harvested and extracellular ATP levels immediately analyzed
using a luciferin–luciferase assay (Sigma-Aldrich). Post challenge,
cells were washed and harvested in 5% trichloroacetic acid.
Experiments were performed in triplicate per setting and on at
least three further occasions. Transfection efficiencies and relative
Cx expression levels were monitored by virtue of GFP autofluores-
cence, real-time PCR, and western blot analysis to detect
2190 Journal of Investigative Dermatology (2012), Volume 132
JA Easton et al.
PEN May Be Caused by Cx26 Mutations
Cx26 expression. Total protein was measured using the Bio-Rad
Laboratories DC protein assay kit (Bio-Rad Laboratories, Hemel
Hempstead, UK) following the manufacturer’s instructions.
Results were then standardized against protein concentration and
results presented as a fold change compared with the control (Wright
et al., 2012).
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